Novo Nordisk announced today that Health Canada has issued marketing authorization with conditions [Notice of Compliance with ...

Learn about semaglutide’s effectiveness and clinical trial results and whether it could be right for you in your MASH treatment plan.

The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...

If you have MASH, GLP-1 medications may help treat the condition. Set yourself up for success with expert advice on diet, exercise, dose scheduling, and more.

Every year in biopharma brings its share of grueling defeats, and 2025 was no different, especially for companies targeting ...

The past 18 months have been absolutely terrible for Novo Nordisk (NYSE: NVO). The Denmark-based drugmaker has faced poor ...

For more than two years it had the entirety of the market for weight-loss drugs to itself. By 2023 sales of Wegovy had ...

Groundbreaking Harvard research reveals gut-produced molecules significantly influence obesity and blood sugar control. These ...

Aviceda Therapeutics ("the Company" or "Aviceda"), a clinical-stage biotechnology company developing innovative therapies for retinal diseases, today announced topline results from its SIGLEC Phase 2b ...

PureHealth Research today announced the launch of its new line of vein health supplements, offering a natural approach to supporting healthy circulation and promoting the appearance of ...

Even so, in an interview with The Economist, Mr Doustdar sounded confident that Novo can recover. His prescription is to push ...

We knew that GLP-1 drugs like Ozempic and Wegovy did more than just help control type 2 diabetes and aid weight loss, but the ...